Treatment of Gambiense Human African Trypanosomiasis — Age ≥ 6 Years, Body Weight ≥ 20 kg

This protocol applies to confirmed gambiense human African trypanosomiasis (HAT) in a specific patient population defined by age, body weight, and the degree of central nervous system involvement at presentation.

Patient criteria

Gambiense human African trypanosomiasis confirmed
Age ≥ 6 years
Body weight ≥ 20 kg
No clinical signs of severe meningo-encephalitic disease, or CSF white blood cell count < 100/µL

Treatment approach

Management in this setting involves a defined combination regimen. The complete protocol — specifying the agents, their doses, routes of administration, and schedule — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Fexinidazole is therefore the first-choice treatment in gambiense HAT patients aged ≥ 6 years and body weight ≥ 20 kg presenting without clinical features consistent with severe meningo-encephalitic HAT or presenting with < 100 WBC/µL in CSF.

If a patient treated with fexinidazole relapses, then NECT should be given.

View source ↗